Dr. Bernhard Hampl Joins ChemWerth Board Of Directors

Peter Werth, the President and CEO of US-based ChemWerth Inc, announced recently that Dr. Bernhard Hampl has joined the company's board of directors. "We are very pleased to add one of the most respected members of the generic pharmaceutical industry to our board of directors. I have known Bernie for many years and have found that in addition to his keen industry insights and strong business acumen, he is a man of immense personal integrity and candor; characteristics which are highly valued at ChemWerth," said Mr. Werth.

Dr. Hampl, received his Ph.D. in pharmaceutical chemistry from Ludwig-Maximillians University in Munich and his distinguished career has included working for Cyanamid GmbH where he served as the company's director of research and development and technical director; Chief Executive Officer of Eon Labs; and, President and CEO of Sandoz U.S.

While CEO of Sandoz, Dr. Hampl also served as a member of the Executive Board of the Generic Pharmaceutical Association, especially advocating a pathway to the approval and future use of bio-generics.

About ChemWerth Inc.

ChemWerth is a world leading developer and supplier of active pharmaceutical ingredients for generic drug formulations. Through its partner companies in China, India, Europe and the United States, ChemWerth seamlessly guides generic formulations through development, manufacturing and supply in compliance with FDA and other global regulated standards. ChemWerth is headquartered in the United States, and has offices in China and India. For more information, visit www.chemwerth.com.

SOURCE: ChemWerth Inc.